Otorhinolaryngological manifestations of the mucopolysaccharidoses.
about
Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapyAnaesthesia and airway management in mucopolysaccharidosis.Respiratory and sleep disorders in mucopolysaccharidosisAge-related functional and histopathological changes of the ear in the MPS I mouse.Vacuolization and alterations of lysosomal membrane proteins in cochlear marginal cells contribute to hearing loss in neuraminidase 1-deficient miceEnzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfataseMucopolysaccharidosis VI.Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey.Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease.Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome.Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case seriesApoptosis status and proliferative activity in mucopolysaccharidosis type I mice tongue mucosa cells.Imaging findings of mucopolysaccharidoses: a pictorial reviewManagement of otolaryngological manifestations in mucopolysaccharidoses: our experience.Correlation Between Flexible Fiberoptic Laryngoscopic and Polysomnographic Findings in Patients with Mucopolysaccharidosis Type VI.Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome.Joint contractures in the absence of inflammation may indicate mucopolysaccharidosis.Perioperative complications in patients diagnosed with mucopolysaccharidosis and the impact of enzyme replacement therapy followed by hematopoietic stem cell transplantation at early age.Prevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference center.Neurophysiology of hearing in patients with mucopolysaccharidosis type IV.Histopathologic changes of the ear in canine models of mucopolysaccharidosis types I and VII.Alterations of mucosa of the larynx and hypopharynx in patients with mucopolysaccharidoses.Auditory characteristics and therapeutic effects of enzyme replacement in mouse model of the mucopolysaccharidosis (MPS) II.Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy
P2860
Q24651989-CD0ACF62-FB60-4096-99DA-CC2D84E0E20CQ26996429-E273B422-B902-4131-9EEA-440D7894797BQ30457547-0FF9D365-7236-47B5-82D0-4FF0162A4C72Q30502089-0C906F4A-5406-479F-8189-00F83BD30490Q33637287-73184DC6-AFF9-4BFD-8554-D4D75EEE02ACQ33688165-A345C1B6-68B8-4374-ACBE-1F6E0884070CQ33863356-428418FF-A039-482F-B1FF-6B7D053B1087Q34002458-5A0FFF71-6041-4DF4-A42E-534F7B5A57ABQ35571515-D99FC9F0-176D-4C6F-8F33-6359977E8CC1Q35669546-01298893-5D6E-4835-9358-475ABBBF639CQ36806851-DD6686C5-C49E-4E57-87BB-400ABE4467CCQ36954229-C11F8E8C-017A-4D01-906C-F12546048F7FQ37064370-7E97DB42-6A72-41FC-8B20-7A8D3B8AA926Q37173777-C38F9C99-4E3C-4279-92D8-37C73659C15CQ37329215-B0667E8D-C3BD-4D77-8CCE-8CD329E671A0Q37341874-5DB59E9C-E099-4605-A5F1-ED1FD3F57F54Q37415918-F17175C7-E46B-4E24-BDB3-B3EE8F3BBE73Q45091974-FF3631E9-D125-4CFE-B583-B5E0BE685919Q45341726-A3D69D09-63F2-4DBE-99A3-1142300B00DFQ50300965-7D470BC9-290E-4215-893A-4A5F329DBFAFQ50436309-2F1B5C6B-15A4-490D-B706-34F5CF3AE0B9Q51564791-12EE93C7-8D56-4B5E-8420-751F3448E89CQ53149495-3EB8415A-2869-4F3B-99D6-619E6F46ED52Q57828810-900EFA14-23E4-45C1-B6BC-C2072107ACA7
P2860
Otorhinolaryngological manifestations of the mucopolysaccharidoses.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Otorhinolaryngological manifestations of the mucopolysaccharidoses.
@ast
Otorhinolaryngological manifestations of the mucopolysaccharidoses.
@en
type
label
Otorhinolaryngological manifestations of the mucopolysaccharidoses.
@ast
Otorhinolaryngological manifestations of the mucopolysaccharidoses.
@en
prefLabel
Otorhinolaryngological manifestations of the mucopolysaccharidoses.
@ast
Otorhinolaryngological manifestations of the mucopolysaccharidoses.
@en
P2093
P1476
Otorhinolaryngological manifestations of the mucopolysaccharidoses
@en
P2093
P304
P356
10.1016/J.IJPORL.2005.01.017
P50
P577
2005-05-01T00:00:00Z